Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies
NCT03198650Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2017
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of acalabrutinib tablet (Variant 1) in B-cell malignancy, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and 1 more (2 arms), sponsored by AstraZeneca. Primary endpoint: Adverse Events, Serious Adverse Events, and Dose-Limiting Toxicities at 28 days. Started Jun 2017; status: completed.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
B-cell malignancychronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03198650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03198650.